ASCO | Berenson Cancer Center https://berensoncancercenter.com Berenson Oncology Mon, 23 Jun 2014 17:36:02 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://berensoncancercenter.com/wp-content/uploads/2023/08/cropped-favicon-32x32.png ASCO | Berenson Cancer Center https://berensoncancercenter.com 32 32 ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma https://berensoncancercenter.com/asco/asco-2014-results-of-the-dose-escalation-portion-of-a-phase-12-study-champion-1-investigating-weekly-carfilzomib-in-combination-with-dexamethasone-for-patients-with-relapsed-or-refractory-multiple/ Mon, 23 Jun 2014 17:35:20 +0000 http://bcc.zdm/?p=489 Abstract No: 8594

Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed … Article

]]>